2023 Maryland Statutes › Health - General › Title 13 - Miscellaneous Health Care Programs › Subtitle 11 - Cancer Prevention, Education, Screening, and Treatment Program › Section 13-1101 - Definitions

(a)    In this subtitle the following words have the meanings indicated.
(b)    “Administrative Component” means the component of the Program established under § 13–1119 of this subtitle.
(c)    “Baseline Cancer Study” means the study conducted under § 13–1103 of this subtitle.
(d)    “Cancer Research Plan” means a plan developed under § 13–1116 of this subtitle.
(e)    “Cigarette Restitution Fund” means the fund that is established under § 7–317 of the State Finance and Procurement Article.
(f)    “Community Health Coalition” means a coalition established under § 13–1109(c)(1) or § 13–1115(b)(1) of this subtitle.
(g)    “Comprehensive Plan for Cancer Prevention, Education, Screening, and Treatment” means a plan developed under § 13–1109(c)(2) or § 13–1115(b)(2) of this subtitle.
(h)    “County” includes Baltimore City.
(i)    “Education” means information provided to the public regarding the purpose of, availability of, and access to screening programs.
(j)    “Federally qualified health center” has the meaning stated in 42 U.S.C. § 254b.
(k)    “Johns Hopkins Institutions” means the Johns Hopkins University and the Johns Hopkins Health System.
(l)    “Local health officer” means:
(1)    The head of a county health department; or
(2)    A person designated by the Department under § 13–1109(g) or § 13–1115(f) of this subtitle.
(m)    “Local Public Health Cancer Grant” means a grant distributed by the Department to a county under §§ 13–1107 through 13–1113 of this subtitle.
(n)    “Local Public Health Component” means the component of the Program that is established under § 13–1107 of this subtitle.
(o)    “Maryland Cancer Registry” means the computerized data system, operated by the Department with the assistance of the Maryland State Council on Cancer Control, that registers cases of cancer that are diagnosed and treated in the State.
(p)    “Maryland Technology Development Corporation” means the entity that is established under Title 10, Subtitle 4 of the Economic Development Article.
(q)    “Minority individual” means a woman or an individual of African American, Hispanic, Native American, or Asian descent.
(r)    “Outreach efforts” means activities that are related to encouraging individuals to seek screening services.
(s)    “Prevention” means activities relating to early detection, screening, and risk factor reduction.
(t)    “Program” means the Cancer Prevention, Education, Screening, and Treatment Program that is established under § 13–1102 of this subtitle.
(u)    “Screening” includes screening, early detection, identification, diagnosis, and outreach efforts associated with screening and early detection programs.
(v)    “Statewide Academic Health Center” means the University of Maryland Medical Group or the Johns Hopkins Institutions.
(w)    “Statewide Academic Health Center Cancer Research Grant” means a grant that is distributed under § 13–1116 of this subtitle.
(x)    “Statewide Academic Health Center Component” means the component established under § 13–1114 of this subtitle.
(y)    “Statewide Academic Health Center Public Health Grant” means a grant that is distributed under § 13–1115 of this subtitle.
(z)    “Statewide Academic Health Center Tobacco–Related Diseases Research Grant” means a grant that is distributed under § 13–1017 of this title.
(aa)    “Statewide Public Health Component” means the component of the Program that is established under § 13–1106 of this subtitle.
(bb)    “Surveillance and Evaluation Component” means the component of the Program that is established under § 13–1103 of this subtitle.
(cc)    “Targeted cancer” means a cancer that is identified by the Department under § 13–1102(d) of this subtitle.
(dd)    “Task Force Report” means the report entitled “Report of the Governor’s Task Force to Conquer Cancer” that was issued in December 1999.
(ee)    “Tobacco–related diseases” means cardiovascular disease, chronic pulmonary disease, peripheral vascular disease, stroke, and infant mortality due to low birth weight.
(ff)    “Treatment” includes appropriate access to:
(1)    Local hospitals, community clinics, physicians, and other health care providers; and
(2)    Clinical trials, transportation, case management, hospice care, and cancer support groups.
(gg)    “Underinsured individual” means an individual:
(1)    For whom the appropriate treatment is not adequately covered by private health insurance, Medicaid, Medicare, or the Maryland Children’s Health Program due to out–of–pocket costs, including required copayments, coinsurance, or deductibles; and
(2)    Who the Department determines does not have the financial means to pay for appropriate treatment.
(hh)    “Uninsured individual” means an individual:
(1)    For whom the appropriate treatment is not covered by private health insurance, Medicaid, Medicare, or the Maryland Children’s Health Program; and
(2)    Who the Department determines does not have the financial means to pay for appropriate treatment.
(ii)    “University of Maryland Medical Group” means the University of Maryland Medical System Corporation, the University of Maryland Medical School, and the University of Maryland, Baltimore Campus.